FAVIPIRAVIR - 200 mgFavipiravir was discovered for antiviral activity against the influenza virus by chemical modification of a pyrazine analog in a pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide). It was approved for medical use in 2014, for the treatment of the new or re-emerging pandemic influenza virus infections....
FAVIPIRAVIR - 400 mgFavipiravir was discovered for antiviral activity against the influenza virus by chemical modification of a pyrazine analog in a pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide). It was approved for medical use in 2014, for the treatment of the new or re-emerging pandemic influenza virus infections....
FAVIPIRAVIR - 800 mgFavipiravir was discovered for antiviral activity against the influenza virus by chemical modification of a pyrazine analog in a pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide). It was approved for medical use in 2014, for the treatment of the new or re-emerging pandemic influenza virus infections....
MOLNUPIRAVIR - 200 mgMolnupiravir, is an antiviral medication that inhibits the replication of certain RNA viruses. It is used to treat COVID-19 in those infected by SARS-CoV-2.. Molnupiravir is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine and exerts its antiviral action by introducing copying errors during viral RNA...